Bristol Myers Squibb stock at USD 62.86 on September 25, 2026, up 2.22 percent

Bristol Myers Squibb stock last traded at USD 62.86 on September 25, 2026, up USD 1.36, or 2.22 percent, from the previous session. Separately, the company reported new Phase 3 data for ZENBEXUS in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma. The data were presented at the International Myeloma Society meeting in Glasgow and published simultaneously in The Lancet Oncology. Bristol Myers Squibb issued the release on September 25, 2026.

Phase 3 multiple myeloma data

The prespecified analysis covered the pivotal EXCALIBER-RRMM trial, which compared the ZENBEXUS combination, identified as ZDd, with daratumumab, bortezomib and dexamethasone, identified as DVd. At a median follow-up of 15.7 months, the primary efficacy population included 420 evaluable patients. The trial’s dual primary endpoints were minimal residual disease-negative complete response rate and progression-free survival.

MRD-negative complete response was recorded in 41.1 percent of patients receiving ZDd, compared with 20.7 percent for DVd. The company reported a 95 percent confidence interval of 11.5 percent to 28.6 percent, a p-value below 0.0001 and an odds ratio of 2.75. The overall response rate was 88.9 percent with ZDd versus 76.1 percent with DVd, while complete response or better reached 45.9 percent versus 24.9 percent.

Safety and regulatory context

Bristol Myers Squibb said the treatment benefit was consistent across prespecified subgroups, including patients with prior lenalidomide exposure and those refractory to lenalidomide. The company also reported that the confirmatory analysis cohort contains 800 patients and that evaluation of the progression-free-survival endpoint remains ongoing. These details frame the reported MRD-negative result as one part of the trial’s broader assessment.

The company reported grade 3 or 4 neutropenia in 84.3 percent of patients receiving ZDd, compared with 11.3 percent in the DVd group. Grade 3 or 4 infections occurred in 39.2 percent and 21.6 percent, respectively. Peripheral sensory neuropathy of any grade was reported in 12.3 percent of ZDd patients and 42.6 percent of DVd patients. Bristol Myers Squibb said neutropenia was mostly managed with granulocyte colony-stimulating factor support and temporary dose interruptions.

ZENBEXUS in combination with daratumumab and hyaluronidase-fihj and dexamethasone received accelerated approval from the U.S. Food and Drug Administration on August 13, 2026, according to the release. The indication covers adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. The company stated that continued approval may depend on verification of clinical benefit in confirmatory trials.

Dividend declaration

In a separate September 16, 2026 announcement, Bristol Myers Squibb said its board declared a quarterly dividend of USD 0.63 per share on the company’s USD 0.10 par value common stock. The dividend is payable on November 2, 2026, to stockholders of record at the close of business on October 2, 2026. Bristol Myers Squibb identified the payment as a quarterly distribution.

On the New York Stock Exchange, Bristol Myers Squibb shares last traded at USD 62.86 at 20:00:02 UTC on September 25, 2026. The daily change was an increase of USD 1.36, equivalent to 2.22 percent, and the previous session price was USD 61.49.